Senzime AB (SEZI) - Net Assets

Latest as of December 2025: Skr304.46 Million SEK ≈ $32.76 Million USD

Based on the latest financial reports, Senzime AB (SEZI) has net assets worth Skr304.46 Million SEK (≈ $32.76 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr369.81 Million ≈ $39.80 Million USD) and total liabilities (Skr65.35 Million ≈ $7.03 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Senzime AB's assets to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr304.46 Million
% of Total Assets 82.33%
Annual Growth Rate 21.03%
5-Year Change 102.19%
10-Year Change 130.88%
Growth Volatility 46.75

Senzime AB - Net Assets Trend (2005–2025)

This chart illustrates how Senzime AB's net assets have evolved over time, based on quarterly financial data. Also explore Senzime AB asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Senzime AB (2005–2025)

The table below shows the annual net assets of Senzime AB from 2005 to 2025. For live valuation and market cap data, see Senzime AB market cap and net worth.

Year Net Assets Change
2025-12-31 Skr304.46 Million
≈ $32.76 Million
-11.97%
2024-12-31 Skr345.86 Million
≈ $37.22 Million
-7.89%
2023-12-31 Skr375.48 Million
≈ $40.41 Million
+43.36%
2022-12-31 Skr261.90 Million
≈ $28.18 Million
+73.93%
2021-12-31 Skr150.58 Million
≈ $16.20 Million
-34.91%
2020-12-31 Skr231.35 Million
≈ $24.90 Million
+41.33%
2019-12-31 Skr163.69 Million
≈ $17.62 Million
-2.22%
2018-12-31 Skr167.41 Million
≈ $18.02 Million
+19.19%
2017-12-31 Skr140.46 Million
≈ $15.12 Million
+6.51%
2016-12-31 Skr131.87 Million
≈ $14.19 Million
+187.86%
2015-12-31 Skr45.81 Million
≈ $4.93 Million
+3.92%
2014-12-31 Skr44.08 Million
≈ $4.74 Million
+17.67%
2013-12-31 Skr37.46 Million
≈ $4.03 Million
+17.12%
2012-12-31 Skr31.99 Million
≈ $3.44 Million
+14.79%
2011-12-31 Skr27.87 Million
≈ $3.00 Million
+27.25%
2010-12-31 Skr21.90 Million
≈ $2.36 Million
+31.80%
2009-12-31 Skr16.61 Million
≈ $1.79 Million
-9.39%
2008-12-31 Skr18.34 Million
≈ $1.97 Million
+96.51%
2007-12-31 Skr9.33 Million
≈ $1.00 Million
+23.62%
2006-12-31 Skr7.55 Million
≈ $812.29K
+12.74%
2005-12-31 Skr6.70 Million
≈ $720.49K
--

Equity Component Analysis

This analysis shows how different components contribute to Senzime AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 77507600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock Skr19.65 Million 6.45%
Other Comprehensive Income Skr-374.00K -0.12%
Other Components Skr1.06 Billion 348.24%
Total Equity Skr304.46 Million 100.00%

Senzime AB Competitors by Market Cap

The table below lists competitors of Senzime AB ranked by their market capitalization.

Company Market Cap
Yew Lee Pacific Group Berhad
KLSE:0248
$80.18 Million
Cheng Fwa Industrial Ltd
TWO:5426
$80.19 Million
Ispire Technology Inc. Common Stock
NASDAQ:ISPR
$80.21 Million
Farmsco
KO:036580
$80.21 Million
Highland Copper Company Inc.
V:HI
$80.10 Million
Ibkimyoung Co. Ltd
KQ:339950
$80.08 Million
Progress-Werk Oberkirch AG
XETRA:PWO
$80.00 Million
Space Shuttle Hi-Tech Co Ltd
TW:2440
$79.99 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Senzime AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 345,857,000 to 304,461,000, a change of -41,396,000 (-12.0%).
  • Net loss of 137,419,000 reduced equity.
  • Share repurchases of 104,243,000 reduced equity.
  • New share issuances of 104,243,000 increased equity.
  • Other comprehensive income decreased equity by 9,476,000.
  • Other factors increased equity by 105,499,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr-137.42 Million -45.14%
Share Repurchases Skr104.24 Million -34.24%
Share Issuances Skr104.24 Million +34.24%
Other Comprehensive Income Skr-9.48 Million -3.11%
Other Changes Skr105.50 Million +34.65%
Total Change Skr- -11.97%

Book Value vs Market Value Analysis

This analysis compares Senzime AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.29x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 1.54x to 2.29x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2009-12-31 Skr3.07 Skr4.74 x
2010-12-31 Skr2.97 Skr4.74 x
2011-12-31 Skr3.03 Skr4.74 x
2012-12-31 Skr2.78 Skr4.74 x
2013-12-31 Skr2.87 Skr4.74 x
2014-12-31 Skr3.03 Skr4.74 x
2015-12-31 Skr2.97 Skr4.74 x
2016-12-31 Skr4.66 Skr4.74 x
2017-12-31 Skr3.51 Skr4.74 x
2018-12-31 Skr3.74 Skr4.74 x
2019-12-31 Skr3.22 Skr4.74 x
2020-12-31 Skr4.06 Skr4.74 x
2021-12-31 Skr2.38 Skr4.74 x
2022-12-31 Skr3.88 Skr4.74 x
2023-12-31 Skr4.07 Skr4.74 x
2024-12-31 Skr2.83 Skr4.74 x
2025-12-31 Skr2.07 Skr4.74 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Senzime AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -45.14%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -132.11%
  • • Asset Turnover: 0.28x
  • • Equity Multiplier: 1.21x
  • Recent ROE (-45.14%) is below the historical average (-22.42%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2009 -10.36% -102.10% 0.08x 1.27x Skr-3.38 Million
2010 -10.75% -137.70% 0.07x 1.18x Skr-4.54 Million
2011 -7.54% -115.59% 0.06x 1.14x Skr-4.89 Million
2012 -13.73% -1472.30% 0.01x 1.04x Skr-7.59 Million
2013 -14.94% -453.26% 0.03x 1.03x Skr-9.34 Million
2014 -14.05% -1144.16% 0.01x 1.05x Skr-10.60 Million
2015 -16.55% -4966.72% 0.00x 1.04x Skr-12.16 Million
2016 -7.14% -578.13% 0.01x 1.19x Skr-22.60 Million
2017 -9.27% -6892.59% 0.00x 1.18x Skr-27.07 Million
2018 -15.30% -797.17% 0.02x 1.18x Skr-42.36 Million
2019 -20.57% -501.79% 0.04x 1.15x Skr-50.04 Million
2020 -20.51% -508.14% 0.04x 1.12x Skr-70.58 Million
2021 -54.55% -748.11% 0.06x 1.16x Skr-97.20 Million
2022 -50.67% -945.56% 0.04x 1.23x Skr-158.89 Million
2023 -35.73% -375.20% 0.08x 1.15x Skr-171.70 Million
2024 -34.33% -203.03% 0.14x 1.23x Skr-153.31 Million
2025 -45.14% -132.11% 0.28x 1.21x Skr-167.87 Million

Industry Comparison

This section compares Senzime AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $171,567,428
  • Average return on equity (ROE) among peers: -27.92%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Senzime AB (SEZI) Skr304.46 Million -10.36% 0.21x $80.11 Million
Acarix A/S (ACARIX) $15.12 Million -127.02% 0.21x $33.84 Million
Arcoma AB (ARCOMA) $48.66 Million 5.27% 0.68x $11.55 Million
Bactiguard Holding AB (publ) (BACTI-B) $387.11 Million -0.84% 0.62x $61.64 Million
BICO Group AB (BICO) $2.31 Million 0.00% 2.47x $159.82 Million
Boule Diagnostics AB (BOUL) $295.74 Million 7.87% 0.93x $14.38 Million
CellaVision AB (CEVI) $887.58 Million 17.25% 0.23x $311.10 Million
Clinical Laserthermia Systems AB (publ) (CLS-B) $26.09 Million -70.24% 0.12x $11.57 Million
Chordate Medical Holding AB (CMH) $25.64 Million -77.06% 0.22x $29.05K
C-Rad AB (publ) (CRAD-B) $29.82 Million -34.38% 0.50x $86.08 Million
Duearity AB (DEAR) $-2.39 Million 0.00% 0.00x $331.97K

About Senzime AB

ST:SEZI Sweden Medical Devices
Market Cap
$80.11 Million
Skr744.41 Million SEK
Market Cap Rank
#20043 Global
#355 in Sweden
Share Price
Skr4.74
Change (1 day)
+1.83%
52-Week Range
Skr4.10 - Skr7.27
All Time High
Skr26.50
About

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive … Read more